April 25, 2024 09:25 (IST)
Follow us:
Migraine treatment injection from Dr Reddy's Lab now available in the US
Hyderabad/Princeton-NJ, Apr 19 (IBNS) Promius Pharma LLC, a subsidiary of Dr. Reddy's Laboratories Ltd, has informed on Tuesday that its ZEMBRACE SymTouch (sumatriptan injection) 3 mg, which was approved by the FDA in January 2016 for the acute treatment of migraine with or without aura in adults, is now commercially available in the U.S.
The company said that ZEMBRACE SymTouch is a pre filled, low-dose, ready-to-use, 2-step autoinjector containing 3 mg of sumatriptan, a selective 5-HT1B/ID receptor agonist. Because ZEMBRACE SymTouch is a subcutaneous injection, it may lead to rapid relief of migraine.
Migraineurs often have more than one kind of attack. Different types of medications can be used to treat different types of attacks.
According to Roger Cady, MD, Associate Executive Chairman of the National Headache Foundation “ZEMBRACE SymTouch is a welcome addition to the toolkit for acute treatment of migraine. This 3-mg, easy to-use subcutaneous injection of sumatriptan may be desired by many migraine patients who need a medication that can rapidly treat migraine attacks. Also, the 3-mg dose allows for up to 4 doses of ZEMBRACE SymTouch in a 24-hour period, thus allowing dosing flexibility for patients.”
ZEMBRACE SymTouch is available as a box of 4 autoinjectors.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
Credit card spending grows 27% YoY to Rs 18.26 trillion in FY24: RBI Thu, Apr 25 2024
Mahindra Tractors crosses milestone by selling 40 lakh tractor units Thu, Apr 25 2024
DishTV India expects to touch 30 percent market share at the end of current financial year, says CEO Manoj Dobhal Thu, Apr 25 2024
DCB Bank Q4FY24: PAT grows YoY 9% to Rs 156 cr Wed, Apr 24 2024
NSE launches Derivatives on the Nifty Next 50 Index today Wed, Apr 24 2024
JPMorgan CEO praises PM Modi for doing 'unbelievable' job in India Wed, Apr 24 2024